Cervical Squamous Cell Carcinoma
Conditions
Brief summary
The goal of this clinical trail is to investigate the efficacy and safety of PD-1 antibody Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for patients diagnosed as local advanced cervical carcinoma (FIGO staging IB2-IIB).
Detailed description
This phase I study is being conducted to establish efficacy and safety of Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for patients diagnosed as local advanced cervical carcinoma (FIGO staging IB2-IIB). All enrolled patients will receive same intervention. Treatment naïve patients who are diagnosed as local advanced cervical squamous cell carcinoma will receive Tislelizumab plus TP regimen before surgery for 3 cycles. After treatment, radiographic evaluation will be performed to assess clinical efficacy. Patients who have objective response will undergo radical surgery. Patients who are disease stable or progression will undergo radical chemoradiotherapy. The primary endpoint is major pathological response rate (MPR).
Interventions
DRUGTislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin
* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles * Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none * Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none
Sponsors
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed cervical squamous cell carcinoma. 2. Clinical staging FIGO IB2-IIB, treatment naive. 3. Female patients aged≥18 years. 4. ECOG performance status 0 or 1, expected lifetime≥3 months. 5. Adequate organ function: Absolute neutrophil count (ANC) ≥1.5x109/L, White blood count ≥3.5x109/L, Platelets ≥75x109/L, Hemoglobin (Hb) ≥90g/L, ALT/AST ≤2.5x ULN, Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN. 6. HBV infected patients (inactive/asymptomatic carrier, chronic or active) with HBV DNA\<500IU/ml (or 2500 copies/ml). 7. Pregnancy test of female patients with fertile activity should be negative within 7 days before enrollment. Patients should keep contraception during treatment. 8. Willingness and ability to comply with the protocol for the duration of the study including scheduled visits, examinations, investigations and treatment plans with informed consent form.
Exclusion criteria
1. Pregnancy or children bearing potential. 2. brain or meningeal metastasis. 3. With second primary malignant diseases. 4. With uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or patients who should receive long-term glucocorticoid treatment (\>10mg/d prednisone). 5. With uncontrollable complications 6. Inadequate organ function 7. Known hypersensitivity reaction to any of the study drugs or components. 9\. Other unsuitable conditions determined by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major pathological response (MPR) rate | Up to approximately 8 weeks following completion of neoadjuvant treatment | Major pathological response rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathological Complete Response (pCR) Rate | Up to approximately 8 weeks following completion of neoadjuvant treatment | rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy. |
| Objective response rate (ORR) | Up to 30 days after last completion of neoadjuvant treatment | Objective Response Rate is defined as the percentage of patients with a documented complete response or partial response (CR + PR) based on RECIST v1.1. |
| Relapse free survival (RFS) | Up to approximately 36 months | Relapse free survival is defined as the time from surgery to first local, regional, or distant tumor recurrence or metastasis, or deaths. |
| Adverse Events | Up to approximately 12 months | All patients who have received at least one dose of treatment will be included in the safety analysis. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Overall survival (OS) | Up to approximately 60 months | Overall survival is defined as the time from signing ICF until death from any cause. |
| Disease free survival (DFS) | Up to approximately 36 months | disease-free survival (DFS) is defined as surgery until documented disease recurrence or death from any cause in all patients (ITT population) who undergo surgery |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarkers analysis | Up to approximately 12 months | The association between biomarkers expression (eg. PD-L1 CPS) in primary tumor and efficacy. |
Countries
China
Contacts
Primary ContactYan Shi
Outcome results
None listed